Home  |  Contact

Cellosaurus HepaRG (CVCL_9720)

[Text version]

Cell line name HepaRG
Synonyms Hepa-RG
Accession CVCL_9720
Resource Identification Initiative To cite this cell line use: HepaRG (RRID:CVCL_9720)
Comments Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652.
Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO.
Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection.
Omics: Deep proteome analysis.
Omics: Membrane proteome analysis.
Omics: miRNA expression profiling.
Omics: Transcriptome analysis.
Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line.
Disease Hepatitis C infection (NCIt: C3098)
Hepatocellular carcinoma (NCIt: C3099)
Hepatocellular carcinoma (ORDO: Orphanet_88673)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_FA14 (Hepa-SC)CVCL_JJ68 (HepaRG CYP3A4G/7R clone 3)CVCL_XI49 (HepaRG-CAR)
CVCL_JY39 (HepaRG-hNTCP)CVCL_WL73 (HPR116)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
Web pages http://www.heparg.com/
http://triangleresearchlabs.net/products-hepatocytes/nospin-heparg/
https://www.thermofisher.com/order/catalog/product/HPRGC10
Publications

PubMed=12432097; DOI=10.1073/pnas.232137699
Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C.
Infection of a human hepatoma cell line by hepatitis B virus.
Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002)

PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003
Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C.
The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Chem. Biol. Interact. 168:66-73(2007)

PubMed=17393521; DOI=10.1002/hep.21536
Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A.
Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.
Hepatology 45:957-967(2007)

Patent=US7456018
Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S.
Human hepatoma lines, methods for obtaining same and uses thereof.
Patent number US7456018, 25-Nov-2008

PubMed=20228232; DOI=10.1124/dmd.109.031831
Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.
A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
Drug Metab. Dispos. 38:988-994(2010)

PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13
Marion M.-J., Hantz O., Durantel D.
The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.
Methods Mol. Biol. 640:261-272(2010)

PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004
Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V.
Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.
Biochem. Pharmacol. 81:1255-1261(2011)

PubMed=22568886; DOI=10.1517/17425255.2012.685159
Andersson T.B., Kanebratt K.P., Kenna J.G.
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.
Expert Opin. Drug Metab. Toxicol. 8:909-920(2012)

PubMed=22594799; DOI=10.3109/13813455.2012.683442
Samanez C.H., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B.
The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.
Arch. Physiol. Biochem. 118:102-111(2012)

PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008
Antherieu S., Chesne C., Li R., Guguen-Guillouzo C., Guillouzo A.
Optimization of the HepaRG cell model for drug metabolism and toxicity studies.
Toxicol. In Vitro 26:1278-1285(2012)

PubMed=22857383; DOI=10.1186/1477-5956-10-47
Sokolowska I., Dorobantu C., Woods A.G., Macovei A., Branza-Nichita N., Darie C.C.
Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.
Proteome Sci. 10:47-47(2012)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)

PubMed=26160117; DOI=10.1093/toxsci/kfv136
Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.
Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.
Toxicol. Sci. 147:412-424(2015)

PubMed=26694163; DOI=10.1371/journal.pone.0144924
Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M.
Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.
PLoS ONE 10:E0144924-E0144924(2015)

PubMed=27169750; DOI=10.1038/srep24709
Sharanek A., Burban A., Burbank M., Le Guevel R., Li R., Guillouzo A., Guguen-Guillouzo C.
Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.
Sci. Rep. 6:24709-24709(2016)

PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2
Ni Y., Urban S.
Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes.
Methods Mol. Biol. 1540:15-25(2017)

PubMed=28904299; DOI=10.2131/jts.42.641
Tomida T., Ishimura M., Iwaki M.
A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.
J. Toxicol. Sci. 42:641-650(2017)

Cross-references
Cell line collections Millipore; C103485 - Discontinued
Ontologies BTO; BTO:0005736
EFO; EFO_0001186
Other Wikidata; Q54882834
Polymorphism and mutation databases Cosmic; 2162524
Entry history
Entry creation06-Jun-2012
Last entry updated12-Mar-2020
Version number20